UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000063648
Receipt number R000071076
Scientific Title Activity Pacing-Based Coaching Through Notifications to Enhance Self-Efficacy in Cancer Survivors
Date of disclosure of the study information 2026/11/16
Last modified on 2026/11/16 17:37:59

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A pilot study of AI chatbot notifications to support confidence in being physically active among breast and gynecological cancer survivors

Acronym

ACT

Scientific Title

Activity Pacing-Based Coaching Through Notifications to Enhance Self-Efficacy in Cancer Survivors

Scientific Title:Acronym

ACT

Region

Japan


Condition

Condition

Breast and gynecological cancer survivors

Classification by specialty

Not applicable

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To preliminarily evaluate whether morning notifications prompting exercise goal setting and evening notifications prompting achievement reporting improve exercise and physical activity self-efficacy compared with no notifications, using a behavioral science-based AI chatbot on LINE for activity pacing support in breast and gynecological cancer survivors. Secondary objectives are to explore behavioral changes, physical activity, cancer-related fatigue, and usability. The same AI chatbot is available in both periods; the study evaluates the added effect of scheduled notifications for behavior change support.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

Exercise and physical activity self-efficacy, assessed using two items with four response categories developed based on a health checkup questionnaire, on Days 1, 15, 29, and 43. Change in period 1 is Day 15 minus Day 1, and change in period 2 is Day 43 minus Day 29. The difference in change between the notification and no-notification periods will be estimated with equal weighting of the two allocation sequences, with a 95% confidence interval.

Key secondary outcomes

1) Self-reported exercise goals and goal achievement during the notification period.
2) Physical activity: Global Physical Activity Questionnaire (GPAQ, 16 items), Days 1, 15, 29, and 43.
3) Cancer-related fatigue: Cancer Fatigue Scale (15 items), Days 1, 15, 29, and 43.
4) Stage of behavior change (one item), Days 1, 15, 29, and 43.
5) Usability: UMUX-LITE (two items, seven-point response scale), Days 15 and 43.
6) LINE chat text and timestamped usage logs throughout study participation.


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

No treatment

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Educational,Counseling,Training

Type of intervention

Behavior,custom

Interventions/Control_1

Sequence A (notifications first; target n=50): On Days 1-14, participants use a behavioral science-based AI chatbot on LINE. A daily 07:00 notification proposes one exercise goal and prompts goal setting; a daily 20:00 notification prompts achievement reporting. Notification times are adjustable by up to one hour in 30-minute increments. Days 15-28 constitute a 14-day washout period. On Days 29-42, the no-notification condition uses the same chatbot, responding only to participant-initiated messages. Both conditions use the same AI chatbot and provide access to exercise videos. Behavior change support uses goal setting, self-monitoring, feedback, and encouragement. The AI does not provide diagnosis, treatment decisions, or medical exercise prescriptions. Questionnaires are administered on Days 1, 15, 29, and 43. Participation is through Day 43, up to 48 days including the final questionnaire deadline.

Interventions/Control_2

Sequence B (no notifications first; target n=50): On Days 1-14, the no-notification condition uses the same AI chatbot on LINE, responding only to participant-initiated messages. Days 15-28 constitute a 14-day washout period. On Days 29-42, daily notifications are provided at 07:00 to propose one exercise goal and prompt goal setting, and at 20:00 to prompt achievement reporting. Notification times are adjustable by up to one hour in 30-minute increments. Both conditions use the same AI chatbot and provide access to exercise videos. Behavior change support uses goal setting, self-monitoring, feedback, and encouragement. The AI does not provide diagnosis, treatment decisions, or medical exercise prescriptions. Questionnaires are administered on Days 1, 15, 29, and 43. Participation is through Day 43, up to 48 days including the final questionnaire deadline.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Female

Key inclusion criteria

Participants must meet all of the following criteria:
1) Provide electronic informed consent.
2) Female and aged 18 years or older at consent.
3) Have a self-reported diagnosis of breast or gynecological cancer.
4) Own a smartphone, be able to use LINE, and be able to enable notifications.
5) Be able to continue participation for up to 48 days, including the final questionnaire response deadline.

Key exclusion criteria

Any of the following:
1) Physician-imposed exercise restrictions because of bone metastases, severe heart disease, or another condition contraindicating exercise.
2) PHQ-2 total score of 3 or higher.
3) Pain interference with daily activities rated as quite a bit or very much on the PRO-CTCAE.
4) Currently prescribed exercise therapy.

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Akiko
Middle name
Last name Hanai

Organization

Chiba University

Division name

Faculty of Informatics

Zip code

263-8522

Address

1-33 Yayoi-cho, Inage-ku, Chiba, Chiba, Japan

TEL

043-290-2708

Email

akiko.hanai@chiba-u.jp


Public contact

Name of contact person

1st name Akiko
Middle name
Last name Hanai

Organization

Chiba University

Division name

Faculty of Informatics

Zip code

263-8522

Address

1-33 Yayoi-cho, Inage-ku, Chiba, Chiba, Japan

TEL

043-290-2708

Homepage URL


Email

akiko.hanai@chiba-u.jp


Sponsor or person

Institute

Japan Institute for Health Security

Institute

Department

Personal name

Yoichi Shimizu


Funding Source

Organization

Ministry of Education, Culture, Sports, Science and Technology / Japan Society for the Promotion of Science (JSPS KAKENHI JP24K22219)

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor

Faculty of Informatics, Chiba University; Institute for Cancer Control, National Cancer Center Japan; Faculty of Nursing, Iwate Prefectural University

Name of secondary funder(s)

SECOM Science and Technology Foundation (Challenging Research Grant; principal investigator: Akiko Hanai)


IRB Contact (For public release)

Organization

Ethics Review Committee, Japan Institute for Health Security

Address

1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan

Tel

03-3202-7181

Email

kenkyu-shinsa@jihs.go.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

千葉大学(千葉県)、国立健康危機管理研究機構 国立看護大学校(東京都)、国立がん研究センター(東京都)、岩手県立大学(岩手県)


Other administrative information

Date of disclosure of the study information

2026 Year 11 Month 16 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD

The study protocol does not specify a plan to share individual participant data outside the research team.

IPD sharing Plan description

Data provided to participating research institutions and authorized analysts are limited to analysis datasets from which direct identifiers have been removed. Linkage keys and administrative data will not be provided. Any use for a new research purpose beyond the present study requires the necessary ethics review and related procedures.


Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2026 Year 08 Month 18 Day

Date of IRB

2026 Year 10 Month 15 Day

Anticipated trial start date

2026 Year 11 Month 05 Day

Last follow-up date

2027 Year 01 Month 03 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2026 Year 11 Month 16 Day

Last modified on

2026 Year 11 Month 16 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000071076